For the 57 ( 9 % ) patients with BRAF ( V600K ) disease , median overall survival in the vemurafenib group was 145 months ( 95 % CI 112-not estimable ) compared with 76 months ( 61-166 ) in the dacarbazine group ( HR 043 [ 95 % CI 021-090 ] ; p = 0024 ) ; median progression-free survival was 59 months ( 95 % CI 44-90 ) and 17 months ( 14-29 ) , respectively ( HR 030 [ 95 % CI 016-056 ] ; p < 00001 ) .